Collectively, our data solidly showed that MYOCD recruited PRMT5/MEP50 methyltransferase complex and epigenetically modified TGFBR2 promoter region to silence its transcription in lung cancer cells. This evidence concerns the gene TGFBR2 and lung carcinoma.